Case Review Form

      * Denotes required field.

      Title

      * First Name

      * Last Name

      * Email Address

      * Phone Number

      Cell Phone Number

      Office Phone Number

      Street Address

      Apartment/Suite

      City

      State

      Zip Code

      Please provide the best method and times to contact you:

      Date of birth of injured person
      (mm-dd-yyyy):

      Name of drug:

      Date you started taking the drug (mm-yyyy):

      Date you stopped taking the drug (mm-yyyy):

      Please describe any side effects:

      Other Info:

      No Yes, I agree to the Parker & Waichman LLP disclaimers.Click here to review all.

      Yes, I would like to receive the Parker & Waichman LLP monthly newsletter, InjuryAlert.

      please do not fill out the field below.

FDA Analysis Question Long-Term Bisphosphonate Use

Filed May 10th, 2012 Laurie

A new Food and Drug Administration analysis published in The New England Journal of Medicine on Wednesday found little if any benefit from the use of popular bone-building drugs called bisphosphonates after three to five years of use. The analysis suggested caution in patients using the drugs long-term, but stopped short of issuing specific recommendations.

Recent debate over the effectiveness of bisphosphonates in women who use them over the course of several years prompted the FDA’s review. Popular bisphosphonate drugs include Fosamax, Boniva, Actonel, and Reclast. Doctors and researchers are concerned that after years of use, bisphosphonates may actually lead to weaker bones in some women, in rare cases.

Weaker bones could equal adverse events for women, including unusual femur fractures.

Be Sociable, Share!

Comments are closed.

Click Here Now, to Have an Attorney Answer Your
Medicinal Drug Injuries Questions
No Cost - No Obligation!